NM-3

CAS No. 181427-78-1

NM-3( —— )

Catalog No. M34669 CAS No. 181427-78-1

NM-3 is an orally available anti-angiogenic inhibitor with anti-tumour activity.NM-3 is used as a radiation modulator in vitro and in vivo.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 416 In Stock
5MG 456 In Stock
10MG 653 In Stock
25MG 1026 In Stock
50MG 1376 In Stock
100MG 1851 In Stock
200MG Get Quote In Stock
500MG 3646 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NM-3
  • Note
    Research use only, not for human use.
  • Brief Description
    NM-3 is an orally available anti-angiogenic inhibitor with anti-tumour activity.NM-3 is used as a radiation modulator in vitro and in vivo.
  • Description
    NM-3 is an isocoumarin with antiarthritic and antiangiogenic effects. NM-3 is an orally active antiangiogenic agent with low toxicity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis | Reactive Oxygen Species
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    181427-78-1
  • Formula Weight
    264.23
  • Molecular Formula
    C13H12O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1C=2C(C=C(C(C(O)=O)C)O1)=CC(OC)=CC2O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. T Nakashima, et al. Inhibition of angiogenesis by a new isocoumarin, NM-3. J Antibiot (Tokyo). 1999 Apr;52(4):426-8. ?
molnova catalog
related products
  • Millepachine

    Millepachine is a natural product found in the Chinese herbal medicine with strong antitumor effects against numerous human cancer cells.

  • Protein kinase inhib...

    Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.

  • Bomedemstat ditosyla...

    Bomedemstat ditosylate (IMG-7289 ditosylate) is an orally active lysine-specific demethylase 1 (LSD1) inhibitor with antitumor activity that potentiates the response to PD-1 inhibition in a homozygous model of SCLC, inhibits cancer cell proliferation, and induces apoptosis.